Billiontoone (NASDAQ:BLLN) Announces Earnings Results

Billiontoone (NASDAQ:BLLN) posted its earnings results on Wednesday. The company reported $0.15 EPS for the quarter, FiscalAI reports. The company had revenue of $109.45 million for the quarter.

Billiontoone Price Performance

BLLN stock traded up $7.72 during trading on Wednesday, hitting $149.97. The company had a trading volume of 885,534 shares, compared to its average volume of 505,325. The firm has a market capitalization of $6.90 billion and a price-to-earnings ratio of 272.67. The company has a current ratio of 10.92, a quick ratio of 10.58 and a debt-to-equity ratio of 0.18. The business has a 50 day moving average of $115.55 and a 200 day moving average of $93.87. Billiontoone has a fifty-two week low of $61.96 and a fifty-two week high of $150.44.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on BLLN shares. JPMorgan Chase & Co. boosted their price objective on Billiontoone from $120.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Weiss Ratings upgraded Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. BTIG Research lowered their price target on shares of Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Finally, Guggenheim initiated coverage on shares of Billiontoone in a report on Monday, June 29th. They issued a “buy” rating and a $125.00 price objective on the stock. Six research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $126.00.

Insider Buying and Selling

In other news, SVP Bosch John Roderick Ten sold 1,416 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $120.00, for a total value of $169,920.00. Following the sale, the senior vice president owned 33,552 shares of the company’s stock, valued at approximately $4,026,240. The trade was a 4.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Nancy Joann Johnson sold 801 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $124.91, for a total transaction of $100,052.91. Following the transaction, the insider owned 21,099 shares of the company’s stock, valued at approximately $2,635,476.09. This trade represents a 3.66% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 157,049 shares of company stock worth $17,328,861. Company insiders own 50.22% of the company’s stock.

Institutional Investors Weigh In On Billiontoone

Large investors have recently modified their holdings of the stock. Massachusetts Financial Services Co. MA acquired a new stake in shares of Billiontoone during the fourth quarter worth $13,373,000. Baillie Gifford & Co. purchased a new position in shares of Billiontoone in the fourth quarter worth approximately $103,786,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Billiontoone during the fourth quarter valued at approximately $1,348,000. UBS Group AG purchased a new stake in shares of Billiontoone in the 4th quarter valued at approximately $2,586,000. Finally, Renaissance Capital LLC acquired a new position in Billiontoone in the 4th quarter worth approximately $201,000.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.